Anemias in Oncology: Potential of Maintenance Therapy

Snegovoi, AV; Vb, Larionova; Manzyuk, LV; Kononenko, I. N.

doi:10.21320/2500-2139-2016-9-3-326-35

Clin oncohematol

2016

DOI: 10.21320/2500-2139-2016-9-3-326-35

|View full text |Cite

Anemias in Oncology: Potential of Maintenance Therapy

AV Snegovoi¹,

Larionova Vb²,

LV Manzyuk³

et al.

Abstract: Развитие анемии в период химио-или химиолучевой терапии злокачественных опухолей является серьезным нежелательным явлением, отрицательно влияющим на качество жизни и эффективность проводимого лечения. В связи с этим ведущие консенсусные комиссии NCCN, ESMO, ASCO, RUSSCO разработали и постоянно обновляют рекомендации по диагностике и лечению анемии у онкологических больных. В статье представлены современные данные о патогенезе и методах лечения анемии у онкологических больных, в т. ч. использование стимуляторов… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2020

2021

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Characteristic of Anemic Syndrome in Oncologic Patients With Sepsis in the Early Post-Operative Period

Blindar

Dobrovolskaya

Зубрихина

et al. 2020

RCLD

View full text Add to dashboard Cite

A study of the main indicators of red blood (RBC, HGB, HCT, MCV, MCH) and the concentration of EPO, sTfR in 9 cancer patients with anemic syndrome (AS) against sepsis was carried out. Among them, patients with chronic disease anemia (ACh), with normocytic, normochromic characteristics of red blood cells and low hematocrit predominated. In 2 patients, microcytosis and erythrocyte hypochromia were noted, the concentration of sTfR was significantly higher than normal (0.9 ± 0.07 μg / ml), amounted to 2.7 μg / ml in one of them and 1.9 μg / ml in the other, which testified to t iron deficiency erythropoiesis (IDE) on the background of the ACh,. In 7 patients with ACh without IDE, sTfR values were within the normal range (0.1-1.2) μg / ml, the median was 0.5 μg/ml. In all patients with sepsis, the production of EPO was inadequate for the severity of the AS, to a lesser extent in patients with IDE. The average EPO production in the group was 19.4 ± 5.1 (7.7-52.8) mU / ml, median = 12.1 mE / ml. Further studies of EPO, sTfR are planned in order to determine their role in therapeutic tactics in the correction of AS in cancer patients with sepsis.

show abstract

Characteristic of Anemic Syndrome in Oncologic Patients With Sepsis in the Early Post-Operative Period

Blindar

Dobrovolskaya

Зубрихина

et al. 2020

RCLD

View full text Add to dashboard Cite

show abstract

Analysis of economic efficiency of iron deficiency anemia therapy in patients with malignant tumors

Саевец

Alekseeva

Таратонов

et al. 2021

jour

View full text Add to dashboard Cite

Introduction. Correction of iron deficiency anemia in patients with malignant neoplasms is an important aspect affecting the quality of life and the effectiveness of special treatments. At the same time, the therapy of comorbid conditions significantly increases the cost of treating cancer patients.The aim of the study was to conduct a comparative pharmacoeconomic analysis of the two most common methods for correcting iron deficiency anemia in cancer patients: transfusion of erythrocyte suspension and intravenous iron preparations using iron carboxymaltose as an example.Materials and methods. An observational, analytical, cohort study was carried out, which included 120 cancer patients. The patients underwent laboratory examination. The tests were assessed: a general blood test with an assessment of the morphological characteristics of erythrocytes, serum iron, ferritin, CRP, total protein. An analysis of the costs of iron deficiency anemia therapy was carried out, taking into account the procurement cost of drugs.Results. It is economically more profitable to use intravenous iron preparations in comparison with transfusion of erythrocyte suspension for the treatment of iron deficiency anemia in patients with malignant neoplasms. The cost of correcting iron deficiency anemia per patient was: when treated with carboxymaltosate iron (Ferinject): 7943.96 rubles, with transfusion of erythrocyte suspension: 16856.40 rubles.Conclusion. In the treatment of anemia in patients with malignant neoplasms with blood preparations (erythrocyte suspension), an improvement in hematological parameters is noted earlier and to a greater extent than with the use of iron preparation carboxymaltozate («Ferinject»). Nevertheless, the duration of the clinical effect when using erythrocyte suspension is lower than that of a parenteral iron preparation.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Anemias in Oncology: Potential of Maintenance Therapy

Cited by 2 publications

References 28 publications

Characteristic of Anemic Syndrome in Oncologic Patients With Sepsis in the Early Post-Operative Period

Characteristic of Anemic Syndrome in Oncologic Patients With Sepsis in the Early Post-Operative Period

Analysis of economic efficiency of iron deficiency anemia therapy in patients with malignant tumors

Contact Info

Product

Resources

About